FTH Faeth Therapeutics Inc.

Price (delayed)

$28.29

Market cap

$37.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$142.72

Enterprise value

-$113.32M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach ...

Highlights
The quick ratio has soared by 187% from the previous quarter and by 118% YoY
FTH's debt has plunged by 68% YoY and by 31% from the previous quarter

Key stats

What are the main financial stats of FTH

FTH stock price

How has the Faeth Therapeutics stock price performed over time
Intraday
1.91%
1 week
9.35%
1 month
15.28%
1 year
295.11%
YTD
165.14%
QTD
13.16%

Financial performance

How have Faeth Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$185.64M
Net income
-$184.46M
Gross margin
N/A
Net margin
N/A

Price vs fundamentals

How does FTH's price correlate with its fundamentals

Growth

What is Faeth Therapeutics's growth rate over time

Valuation

What is Faeth Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Efficiency

How efficient is Faeth Therapeutics business performance

Dividends

What is FTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FTH.

Financial health

How did Faeth Therapeutics financials performed over time
The quick ratio has soared by 187% from the previous quarter and by 118% YoY
Faeth Therapeutics's current ratio has soared by 184% from the previous quarter and by 111% YoY
FTH's debt is 101% more than its equity
FTH's debt to equity has dropped by 113% since the previous quarter and by 110% year-on-year
FTH's debt has plunged by 68% YoY and by 31% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.